These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 8071388)

  • 1. Intravesical BCG therapy of superficial bladder cancer: study of adverse effects.
    Galván L; Ayani I; Arrizabalaga MJ; Rodriguez-Sasiain JM
    J Clin Pharm Ther; 1994 Apr; 19(2):101-4. PubMed ID: 8071388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravesical chemotherapy (mitomycin C) versus immunotherapy (bacillus Calmette-Guérin) in superficial bladder cancer.
    Rintala E; Jauhiainen K; Alfthan O; Hansson E; Juusela H; Kanerva K; Korhonen H; Permi J; Sotarauta M; Vaalasti T
    Eur Urol; 1991; 20(1):19-25. PubMed ID: 1743226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy with bacille Calmette-Guérin in patients with superficial transitional cell carcinoma of the bladder associated with bilharziasis.
    Wishahi MM; Ismail IM; el-Sherbini M
    Br J Urol; 1994 Jun; 73(6):649-54. PubMed ID: 8032832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Do bacteriostatic urethral lubricants affect the clinical efficacy of intravesical bacillus Calmette-Guérin therapy?
    Loertzer H; Brake M; Horsch R; Keller H
    Urology; 2001 May; 57(5):900-5. PubMed ID: 11337290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective randomized comparison of intravesical with percutaneous bacillus Calmette-Guerin versus intravesical bacillus Calmette-Guerin in superficial bladder cancer.
    Lamm DL; DeHaven JI; Shriver J; Sarosdy MF
    J Urol; 1991 Apr; 145(4):738-40. PubMed ID: 2005691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunoprophylaxis of superficial bladder cancer: a prospective and randomized comparison of oral versus intravesical Bacillus Calmette-Guerin.
    Netto Júnior NR; Levi d'Ancona CA; Claro JF; Ilari O
    Arch Esp Urol; 1991 Oct; 44(8):1025-8. PubMed ID: 1796850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-dose bacille Calmette-Guérin (BCG) therapy in superficial high-risk bladder cancer: a phase II study with the BCG strain Connaught Canada.
    Mack D; Frick J
    Br J Urol; 1995 Feb; 75(2):185-7. PubMed ID: 7850323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complications of bacillus Calmette-Guerin therapy in superficial urothelial cancer: clinical analysis and implications.
    Suzuki S; Shinohara N; Harabayashi T; Taniguchi A; Haga K; Sato S; Sakamoto K; Koyanagi T
    Int J Clin Oncol; 2002 Oct; 7(5):289-93. PubMed ID: 12402062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of intravesical bacillus Calmette-Guérin in the treatment of superficial transitional cell carcinoma of the bladder: an overview.
    Witjes JA; vd Meijden AP; Debruyne FM
    Urol Int; 1990; 45(3):129-36. PubMed ID: 2190404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravesical bacillus Calmette-Guérin therapy for T1 superficial bladder cancer.
    Demkow T; Alter A; Wiechno P
    Urol Int; 2008; 80(1):74-9. PubMed ID: 18204238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Intravesical bacillus Calmette-Guerin (BCG) in the treatment of superficial bladder tumors: effect of intravesical BCG on papillary tumors].
    Hagiwara M; Asano T; Iigaya T; Tsukamoto T; Nishida K
    Nihon Hinyokika Gakkai Zasshi; 1986 Oct; 77(10):1623-30. PubMed ID: 3820900
    [No Abstract]   [Full Text] [Related]  

  • 12. Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer.
    Martínez-Piñeiro JA; Jiménez León J; Martínez-Piñeiro L; Fiter L; Mosteiro JA; Navarro J; García Matres MJ; Cárcamo P
    J Urol; 1990 Mar; 143(3):502-6. PubMed ID: 2106041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prophylactic effect of inductive intravesical instillation of Bacillus Calmette-Guerin on postoperative recurrence of bladder cancer].
    Yi SH; Ye G; Wang XW; Jin HS; Zhang YN; Yan ZL
    Ai Zheng; 2008 Nov; 27(11):1208-11. PubMed ID: 19000455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical study of prognostic factors of superficial bladder cancer treated with intravesical bacillus Calmette-Guerin.
    Shinka T; Hirano A; Uekado Y; Ohkawa T
    Br J Urol; 1990 Jul; 66(1):35-9. PubMed ID: 2393797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pitfalls in intravesical immunotherapy of superficial carcinoma of the gallbladder with BCG vaccine].
    Pacík D; Vít V; Turjanica M
    Rozhl Chir; 1997 Jan; 76(1):3-5. PubMed ID: 9182342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Marker tumour responses to the sequential combination of intravesical therapy with mitomycin-C and BCG-RIVM in multiple superficial bladder tumours. Report from the European Organisation for Research and Treatment on Cancer-Genitourinary Group (EORTC 30897).
    Van der Meijden AP; Hall RR; Macaluso MP; Pawinsky A; Sylvester R; Van Glabbeke M
    Eur Urol; 1996; 29(2):199-203. PubMed ID: 8647147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunoprophylactic intravesical application of bacillus Calmette-Guerin after transurethral resection of superficial bladder cancer.
    Librenjak D; Situm M; Eterovic D; Dogas Z; Gotovac J
    Croat Med J; 2003 Apr; 44(2):187-92. PubMed ID: 12698510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal Tuberculosis Following Intravesical Bacillus Calmette-Guérin (BCG) Immunotherapy for the Treatment of Bladder Cancer.
    Bajramovic S; Alic J; Skopljak E; Chikha A; Vesnic S; Smajilbegovic V; Aganovic D
    Med Arch; 2020 Apr; 74(2):146-150. PubMed ID: 32577059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do prognostic parameters of remission versus relapse after Bacillus Calmette-Guérin (BCG) immunotherapy exist?. analysis of a quarter century of literature.
    Saint F; Salomon L; Quintela R; Cicco A; Hoznek A; Abbou CC; Chopin DK
    Eur Urol; 2003 Apr; 43(4):351-60; discussion 360-1. PubMed ID: 12667715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral or intravesical bacillus Calmette-Guerin immunoprophylaxis in bladder carcinoma.
    D'Ancona CA; Netto Júnior NR; Claro JA; Ikari O
    J Urol; 1991 Mar; 145(3):498-501. PubMed ID: 1997698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.